A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MILVEXIAN, AN ORAL FACTOR XIA INHIBITOR, VERSUS APIXABAN IN PARTICIPANTS WITH ATRIAL FIBRILLATION
- Registry ID
- 70033093AFL3002
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- JANSSEN RESEARCH AND DEVELOPMENT LLC
- Start date
- 2023-07-27
- Last update
- 2023-05-10
Conditions
Related clinical trials
- A PHASE 2, RANDOMIZED, MULTICENTER, OPEN-LABEL, BLINDED-ENDPOINT STUDY TO EVALUATE THE
SAFETY OF REGN7508 AND REGN9933, MONOCLONAL ANTIBODIES AGAINST FXI, VERSUS
APIXABAN IN PARTICIPANTS WITH ATRIAL FIBRILLATION (ROXI-ATLAS)
- A RANDOMIZED, PLACEBO-CONTROLLED, PARTICIPANT- AND INVESTIGATOR-BLINDED
STUDY TO EVALUATE THE EFFICACY IN REDUCING ATRIAL FIBRILLATION BURDEN (AFB) AS
WELL AS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL PKN605 IN
PARTICIPANTS WITH ATRIAL FIBRILLATION
- START-POAF -SHORT TERM ANTI-ARRHYTHMIC THERAPY FOR POST-OPERATIVE AF IN
CARDIAC SURGERY PATIENTS (START-POAF) PILOT TRIAL
- USE OF MAGNESIUM PROPHYLAXIS FOR THE PREVENTION OF ATRIAL FIBRILLATION IN CRITICALLY ILL PATIENTS : ATOMIC PILOT
STUDY
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABELACIMAB IN HIGH-RISK PATIENTS WITH ATRIAL FIBRILLATION WHO HAVE BEEN DEEMED UNSUITABLE FOR ORAL ANTICOAGULATION (LILAC), VERSION 1.0 DATED 18 OCTOBER 2022
- A PHASE 2, TWO-STAGE, SERIAL COHORT DOSE ESCALATION AND EXPANSION STUDY OF A SINGLE INTRAVENOUS INFUSION OF HBI 3000 FOR THE CONVERSION OF ATRIAL FIBRILLATION (AF) OF RECENT ONSET
View on source registry